Expertise in
5
conditions

Kai T. Yao

No. 190 The East Jiannan Road, 
Mianyang, CN 
Expertise in
5
conditions
No. 190 The East Jiannan Road, 
Mianyang, CN 
OverviewLocationsClinical Research

Overview

Kai Yao practices in Mianyang, China. Yao is highly rated in 5 conditions, according to our data. Their top areas of expertise are Penile Cancer, Bladder Cancer, Testicular Cancer, Orchiectomy, and Penectomy.

Their clinical research consists of co-authoring 243 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

No. 190 The East Jiannan Road, Mianyang, 621000, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of NL003 in Subject With Critical Limb Ischemia（Rutherford 5）
A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of NL003 in Subject With Critical Limb Ischemia（Rutherford 5）
Enrollment Status: Completed
Publish Date: September 20, 2024
Intervention Type: Genetic, Other
Study Drug: NL003 Hepatocyte Growth Factor cDNA Hybrid
Study Phase: Phase 3
A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of NL003 in Subject With Critical Limb Ischemia(Rutherford 4)
A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of NL003 in Subject With Critical Limb Ischemia(Rutherford 4)
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Genetic, Other
Study Drug: NL003 Hepatocyte Growth Factor-X7 cDNA Hybrid
Study Phase: Phase 3
View 1 Less Clinical Trial

243 Total Publications

Surface Interface-Driven Catalytic Decomposition of Nitroguanidine by Size-Tuned PbCO3 Suppressed Toxic Emissions and Enhanced Thermal Reactivity.
Surface Interface-Driven Catalytic Decomposition of Nitroguanidine by Size-Tuned PbCO3 Suppressed Toxic Emissions and Enhanced Thermal Reactivity.
Journal: Langmuir : the ACS journal of surfaces and colloids
Published: October 17, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Yao's expertise for a condition
ConditionClose
    View All 46 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile